echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Which segments deserve long-term attention when the legislation of biosafety law is speeding up?

    Which segments deserve long-term attention when the legislation of biosafety law is speeding up?

    • Last Update: 2020-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network market analysis] biosafety law is the general term of the legal norms formulated by the state to prevent the ecological risks of modern biotechnology It is understood that biotechnology, on the one hand, provides convenience for human disease prevention and treatment, on the other hand, greatly reduces the technical threshold, intensifies the concealment of misuse, abuse and misuse of technology, and poses a major challenge to biosafety supervision However, over the years, there is a lack of awareness of biosafety issues, many people have not even heard of biosafety issues At present, China's biosafety management system has a series of problems, such as heavy utilization, light supervision and so on Therefore, it is of great significance to speed up biosafety legislation Recently, the legislation of biosafety law has been speeded up, which requires "bringing biosafety into the national security system, systematically planning the national biosafety risk prevention and control system construction, and comprehensively improving the national biosafety governance capacity We should promote the introduction of biosafety laws as soon as possible, and accelerate the construction of national biosafety laws and regulations system and system guarantee system " Experts said that the development of biosafety law will help regulate the research and application of human biotechnology, help the rapid and healthy development of biotechnology, and prevent and reduce the possible harm and loss At the same time, in the form of legal system, industrial policies and science and technology policies that encourage independent innovation are fixed, which can further enhance the national biosafety capacity-building It can be seen that the biosafety legislation is put forward in the current context In this regard, the industry believes that the lack of prevention (in addition to the system and management, the shortage of defense materials and drugs), the future investment in this field is expected to increase, and the related fields are also expected to usher in development opportunities Which segments deserve long-term attention? Combined with the current background, from a long-term perspective, the future segmentation plate in line with the policy development trend deserves attention The industry believes that after the outbreak, the public should pay more attention to the safety precautions for infectious diseases Masks, thermometers, etc may be just needed, and the willingness to vaccinate related preventive biological vaccines will also increase At the same time, the state has strengthened the management and control of biological information and genetic information resources, increased the industry supervision of health and genetic information big data such as gene sequencing, physical examination institutions, third-party diagnostic service institutions, and the industry concentration or rapid improvement In addition, the domestic level will also guarantee and promote the development of China's biotechnology industry in accordance with the law Specifically, affected by the epidemic, the country and the people will pay long-term attention to social public health in the future, and the rigid demand for masks, household medical devices, vaccines and other rigid needs continues, and relevant enterprises with production capacity and technical strength are expected to benefit It is recommended to pay attention to Yuyue medical, kangxinuo biology, etc At the same time, with the strengthening of biological, genetic and other big data supervision, the industry threshold continues to improve, and the industry concentration will continue to improve, and meinian health, golden domain medicine, Dean diagnostics are expected to benefit in the long term In addition, the industry expects that in the future, the country will successively issue corresponding policies to guarantee and encourage the innovation and development of biotechnology industry In this context, the leading enterprises in the industry with innovation and R & D strength will usher in opportunities It is recommended to pay attention to pharmaceutical enterprises with strong innovation and R & D capability for a long time, including Hengrui pharmaceutical, Beida pharmaceutical, etc.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.